Published in Cancer Weekly, April 24th, 2006
Quest Diagnostics developed Leumeta to identify and analyze genetic components of leukemia and lymphoma tumors using blood plasma instead of bone marrow. The assays are designed to measure "tumor load," or the amount of cancer in a patient; detect certain blood cancer markers; and assist the physician in monitoring the impact of treatment. They are the first diagnostic assays available to doctors that directly measure tumor load and identify markers in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.